Alnylam Pharmaceuticals
ALNY
ALNY
282 hedge funds and large institutions have $11.7B invested in Alnylam Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 102 increasing their positions, 65 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
14% more call options, than puts
Call options by funds: $165M | Put options by funds: $144M
14% more capital invested
Capital invested by funds: $10.3B → $11.7B (+$1.43B)
1.69% less ownership
Funds ownership: 95.44% → 93.75% (-1.7%)
Holders
282
Holding in Top 10
14
Calls
$165M
Puts
$144M
Top Buyers
| 1 | +$466M | |
| 2 | +$142M | |
| 3 | +$127M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$98M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$65.6M |
Top Sellers
| 1 | -$269M | |
| 2 | -$116M | |
| 3 | -$90.2M | |
| 4 |
Goldman Sachs
New York
|
-$77M |
| 5 |
PA
Perceptive Advisors
New York
|
-$58.2M |